Denise De Almeida Nagata
About Denise De Almeida Nagata
Denise De Almeida Nagata is a Senior Scientist specializing in IO Clinical Biomarkers at IGM Biosciences, Inc., with a background in veterinary immunology and extensive experience in cancer immunotherapy.
Current Role at IGM Biosciences
Denise De Almeida Nagata serves as a Senior Scientist in the IO Clinical Biomarkers division at IGM Biosciences, Inc. She has held this position since 2021. In her role, she focuses on the development and analysis of clinical biomarkers related to immuno-oncology. Her work contributes to advancing cancer immunotherapy by identifying biomarkers that can improve patient outcomes.
Previous Experience at Genentech
Denise De Almeida Nagata worked at Genentech in two capacities. She was a Senior Scientific Researcher from 2014 to 2019, where she contributed to various research projects. Following this role, she served as a Scientist from 2019 to 2021. During her time at Genentech, she gained significant experience in the field of cancer research and biomarker development.
Academic Background and Post-Doctoral Experience
Denise De Almeida Nagata has a robust academic background, having completed her post-doctoral fellowship at the University of Michigan. She worked in the Department of Internal Medicine from 2008 to 2011 and later in the Department of Pathology from 2011 to 2014. Her post-doctoral training provided her with in-depth knowledge and research experience in immunology and pathology.
Veterinary Background and Transition to Immunology
Denise De Almeida Nagata began her career as a veterinarian, practicing at Universidade Estadual Paulista (UNESP) from 2001 to 2006. She has a background as a veterinarian immunologist, which laid the foundation for her transition into clinical research focused on immuno-oncology. This unique perspective enhances her approach to cancer immunotherapy.
Expertise in Cancer Immunotherapy
Denise De Almeida Nagata possesses expertise in cancer immunotherapy, particularly in the area of clinical biomarkers for immuno-oncology. Her research aims to identify and validate biomarkers that can facilitate the development of effective cancer treatments. This focus is crucial for advancing personalized medicine in oncology.